251 related articles for article (PubMed ID: 28512240)
1. STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.
Dahal LN; Dou L; Hussain K; Liu R; Earley A; Cox KL; Murinello S; Tracy I; Forconi F; Steele AJ; Duriez PJ; Gomez-Nicola D; Teeling JL; Glennie MJ; Cragg MS; Beers SA
Cancer Res; 2017 Jul; 77(13):3619-3631. PubMed ID: 28512240
[TBL] [Abstract][Full Text] [Related]
2. Enhancing immunotherapy of STING agonist for lymphoma in preclinical models.
Sallets A; Robinson S; Kardosh A; Levy R
Blood Adv; 2018 Sep; 2(17):2230-2241. PubMed ID: 30194137
[TBL] [Abstract][Full Text] [Related]
3. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
4. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
5. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
6. HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Hussain K; Liu R; Smith RCG; Müller KTJ; Ghorbani M; Macari S; Cleary KLS; Oldham RJ; Foxall RB; James S; Booth SG; Murray T; Dahal LN; Hargreaves CE; Kemp RS; Longley J; Douglas J; Markham H; Chee SJ; Stopforth RJ; Roghanian A; Carter MJ; Ottensmeier CH; Frendéus B; Cutress RI; French RR; Glennie MJ; Strefford JC; Thirdborough SM; Beers SA; Cragg MS
J Exp Clin Cancer Res; 2022 Apr; 41(1):131. PubMed ID: 35392965
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates.
Li F; Ulrich M; Jonas M; Stone IJ; Linares G; Zhang X; Westendorf L; Benjamin DR; Law CL
Mol Cancer Ther; 2017 Jul; 16(7):1347-1354. PubMed ID: 28341790
[TBL] [Abstract][Full Text] [Related]
8. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.
Hubert P; Heitzmann A; Viel S; Nicolas A; Sastre-Garau X; Oppezzo P; Pritsch O; Osinaga E; Amigorena S
Cancer Res; 2011 Aug; 71(15):5134-43. PubMed ID: 21697279
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
11. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
12. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
Front Immunol; 2019; 10():390. PubMed ID: 30899264
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
Houot R; Goldstein MJ; Kohrt HE; Myklebust JH; Alizadeh AA; Lin JT; Irish JM; Torchia JA; Kolstad A; Chen L; Levy R
Blood; 2009 Oct; 114(16):3431-8. PubMed ID: 19641184
[TBL] [Abstract][Full Text] [Related]
14. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.
Minard-Colin V; Xiu Y; Poe JC; Horikawa M; Magro CM; Hamaguchi Y; Haas KM; Tedder TF
Blood; 2008 Aug; 112(4):1205-13. PubMed ID: 18495955
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Clynes RA; Towers TL; Presta LG; Ravetch JV
Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
[TBL] [Abstract][Full Text] [Related]
16. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
Horton HM; Bernett MJ; Peipp M; Pong E; Karki S; Chu SY; Richards JO; Chen H; Repp R; Desjarlais JR; Zhukovsky EA
Blood; 2010 Oct; 116(16):3004-12. PubMed ID: 20616215
[TBL] [Abstract][Full Text] [Related]
17. Neutrophils mediate antibody-induced antitumor effects in mice.
Albanesi M; Mancardi DA; Jönsson F; Iannascoli B; Fiette L; Di Santo JP; Lowell CA; Bruhns P
Blood; 2013 Oct; 122(18):3160-4. PubMed ID: 23980063
[TBL] [Abstract][Full Text] [Related]
18. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Beers SA; French RR; Chan HT; Lim SH; Jarrett TC; Vidal RM; Wijayaweera SS; Dixon SV; Kim H; Cox KL; Kerr JP; Johnston DA; Johnson PW; Verbeek JS; Glennie MJ; Cragg MS
Blood; 2010 Jun; 115(25):5191-201. PubMed ID: 20223920
[TBL] [Abstract][Full Text] [Related]
19. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
[TBL] [Abstract][Full Text] [Related]
20. The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.
Lykken JM; Tedder TF
Cancer J; 2015; 21(4):351-6. PubMed ID: 26222089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
